Instrument Inactif

Communiqués Mazorro Resources Inc. Deutsche Boerse AG

Actions

Cours en clôture Deutsche Boerse AG Autres places de cotation
- ^EUR	-

11/02/23	Tetra Bio-Pharma Announces Listing to OTCPink Market	PR
22/12/22	REDUVO™ Marketing Approval on the Right Path	PR
06/12/22	Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir	PR
29/11/22	Tetra Bio-Pharma Provides Update on Patent Applications for Novel Therapeutic ARDS-003	PR
27/10/22	Tetra Bio-Pharma Inc. Announces Second Closing of Financing with Alpha Blue Ocean	PR
06/09/22	Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients	PR
10/08/22	Tetra Bio-Pharma Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral Infections	PR
30/05/22	Tetra Bio-Pharma Appoints Chief Financial Officer	PR
16/02/22	Tetra Bio-Pharma Receives $4.5M from the Ministère de l'Économie et de l'Innovation/Investissement Québec	PR
14/02/22	Tetra Bio-Pharma Enters into a Strategic Partnership with Avicanna	PR
29/11/21	QIXLEEF™ Aerosol Meets the Criteria Established by the U.S. FDA for Delivery of Inhalation Aerosols	PR
05/11/21	Tetra Bio-Pharma Inc. Announces Termination of "At-The-Market" Offering	PR
21/10/21	Tetra Bio Pharma : Receives Positive Opinion for Orphan Drug Designation for QIXLEEF™ from the European Medicines Agency	PR
05/10/21	Tetra Bio Pharma : REDUVO™ - A Major Milestone for Tetra Bio-Pharma Inc.	PR
19/12/19	Tetra Bio-Pharma CEO, Dr. Guy Chamberland, Is Featured on the Stock Day Podcast	NE